Despite these positive clinical developments, Amgen and Viking Therapeutics have performed poorly on the stock market in the past 12 months, though progress in this area might eventually help them ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

From battling drought to caring for wildlife, shots from the Earth Photo 2025 competition shortlist show how we are coping ...

Google is rolling out a new image-generating AI model, Imagen 4, that the company claims delivers higher-quality results than ...

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

President Trump’s science adviser called for a return to reproducible and transparent research to kickstart stalled ...

Fortress Biotech, Inc. ("Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...

Photo: Sean Gallup/Getty Images The U.S. is backing away from free trade under President Trump, but much of the rest of the world is not. Since Trump’s election there has been a flurry of ...

Rivian built up a stockpile of batteries for its trucks, SUVs, and commercial vans before and after the election of Donald Trump, a strategy used to soften the blow of the president’s tariffs ...

Mer­ck KGaA said Mon­day it has inked a “de­fin­i­tive agree­ment” to ac­quire Pfiz­er spin­out Spring­Works Ther­a­peu­tics for an eq­ui­ty val­ue of around $3.9 bil­lion ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...